Derek Yuan, MD
Neurology · Johnson City, NYNPI 1548503642
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $68,346 of the $75,398 with a category attached, or 90.6%. AbbVie accounts for 69.6% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $30,364, more than ten times the $787 reported in 2019. Among neurology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $398.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$52K
- Pfizer$21K
- Amgen$378
- SK Life Science, Inc.$260
- Lundbeck LLC$172
- Jazz Pharmaceuticals Inc.$150
- plus $962 from 25 others
What the payments were for
- Consulting fees$1,8002%
- Speaking & faculty fees$68,34691%
- Food & beverage$5,2387%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 61 | $52,495 |
| Pfizer | 53 | $20,982 |
| Amgen | 5 | $378 |
| SK Life Science, Inc. | 11 | $260 |
| Lundbeck LLC | 9 | $172 |
| Jazz Pharmaceuticals Inc. | 2 | $150 |
| Teva Pharmaceuticals USA, Inc. | 1 | $125 |
| Lilly USA, LLC | 7 | $118 |
| EMD Serono, Inc. | 6 | $104 |
| Collegium Pharmaceutical, Inc. | 5 | $73 |
| MDD US Operations, LLC | 4 | $64 |
| Sanofi | 2 | $43 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Impel Pharmaceuticals Inc. | 2 | $40 |
| Boston Scientific | 1 | $33 |
| Assertio Therapeutics, Inc. | 2 | $32 |
| Eisai Inc. | 1 | $32 |
| Merz North America, Inc. | 1 | $31 |
| AstraZeneca | 1 | $30 |
| Sentynl Therapeutics, Inc. | 2 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $14 |
| Biogen | 1 | $13 |
| IBSA Pharma Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| SPR Therapeutics, Inc | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,398 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 26 | $222,253 |
| Nurtec OdtRimegepant Sulfate | 86 | $157,061 |
| UbrelvyUbrogepant | 63 | $110,065 |
| Emgality PenGalcanezumab-Gnlm | 145 | $106,237 |
| Aimovig AutoinjectorErenumab-Aooe | 85 | $70,850 |
| BanzelRufinamide | 12 | $53,603 |
| RytaryCarbidopa/Levodopa | 30 | $41,347 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 49 | $33,930 |
| QuliptaAtogepant | 26 | $29,148 |
| Sumatriptan Succinate | 38 | $4,724 |
| Levetiracetam | 71 | $3,493 |
| Eletriptan HbrEletriptan Hydrobromide | 32 | $3,374 |
| Frovatriptan Succinate | 18 | $2,762 |
| RizatriptanRizatriptan Benzoate | 121 | $2,669 |
| Divalproex Sodium | 37 | $2,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $20,982 | $157,06186 claims |
| AbbVieUbrelvy, Qulipta | $52,495 | $139,21389 claims |
| Eisai Inc.Banzel | $32 | $53,60312 claims |
| Amneal Pharmaceuticals LLCRytary | $43 | $41,34730 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.
Other neurology in Johnson City
- Idan SharonBrooklyn$2.1M
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
- Richard LiptonBronx$753K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.